Anika Therapeutics GAAP EPS of -$0.71 misses by $0.37, revenue of $37.9M beats by $0.54M

• Anika Therapeutics press release (NASDAQ:ANIK): Q1 GAAP EPS of -$0.71 misses by $0.37.
• Revenue of $37.9M (+3.3% Y/Y) beats by $0.54M.

• For the fiscal year 2023, Olo expects to report:

• Revenue in the range of $215.8 million to $217.3 million; and

• Non-GAAP operating income in the range of $12.0 million to $13.2 million.

• Fiscal 2023 Revenue Outlook

• The Company continues to expect its overall revenue for fiscal year 2023 to be between $158 million and $163 million, vs $161.07M Consensus representing growth of 1% to 4% compared to 2022, as growth in OA Pain Management and Joint Preservation and Restoration is offset by lower ancillary Non-Orthopedic revenues.